University Hospital
Strasbourg, 67091, France
NCT Number: NCT02026895
The main objective is to identify new virulence factors produced by Staphylococcus lugdunensis that can be associated with clinical sign of severe infections and identified symptoms. The methodological approach is based on the comparison between the production of toxins by a given S. lugdunensis isolate classified in patients groups according to the infection clinically defined. Each group will be compared to the presence or not of studied virulence factors. Clinical features associated with toxin activity are not known for S. lugdunensis. This comparative approach is based on the hypotheses that drove to the definition of patient groups and their clinical criteria. However, in the absence of the evident correlation between production of toxins and kind of infection, the statistical evaluation will be completed by a multi-varied analysis. This approach has not been choosen first because of the multiple parameters that undergo during infection that may reveal relationships without true correlation. About the number of included patients in each defined group, if one of them does not reach the expected count, we still might extend inclusions to 3-6 months more. The presence of severe infections without usually defined risk is intriguing. For these last patients, we have planned, after their individual consent to achieve an exome sequencing. The obtained data will be compared to available resources for the human genome. By filtering data through usual protocols, we hope to able to focus onto few genes that evoke specific sensitivity to infections, e.g. severe endocarditis due to S. lugdunensis without defined risk.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Not applicable
Strasbourg, 67091, France
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: Participants will be followed for the duration of hospital stay, an expected average of 1 week
Several groups will be compared considering the presence/absence of virulence factors:
Bacteriemic VS non bacteriemic, Deep infection VS Skin/mucosal infection, Foreign body infection VS not, Presence of abscess VS not, Sepsis VS no sepsis, Septic embolism VS not, Portal of entry or not
The following virulence factors will be searched for:
TSST-1, enterotoxins, leukotoxins, epidermolysins, beta-hemolysins, SCIN-CHIPS, Sbi, Efb, SdrE
Time frame: Participants will be followed for the duration of hospital stay, an expected average of 1 week
Characteristics of infection: comorbidities (Charlson score) - history of the disease - clinical, cytological , immunological, inflammatory and organ functions parameters - results of additional tests conducted under their care - response to treatment - morbidity and mortality
Time frame: Genetic blood samples will be analyzed together after the end of inclusion period (18 months)
Time frame: Genetic blood samples will be analyzed together after the end of inclusion period (18 months)
University Hospital, Strasbourg, France
Other
Acronym: VISLISI
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT00548002
Bacteremia, Bacterial Infections
Helsinki, HUS, Finland
View Trial DetailsNCT03153384
Bacteremia, Bacterial Infections
Belfort, France
View Trial DetailsNCT00454285
Bacteremia, Bacterial Infections
Charlotte, North Carolina, United States
View Trial DetailsNCT00093067
Bacteremia, Bacterial Endocarditis
View Trial Details